. Here, it influences systemic Ca 2+ homeostasis by detecting increases in the prevailing circulating concentration of Ca 2+ , which lead to intracellular signalling events that mediate a decrease in parathyroid hormone (PTH) secretion and a reduction in renal tubular Ca 2+ reabsorption 3 ( Fig. 1) . The importance of the CaSR for the regulation of circulating concentrations of Ca 2+ (that is, its calcitropic actions) has been shown by the fact that germline loss-of-function and gain-of-function mutations in genes encoding this GPCR and its intracellular partner proteins result in inherited hypercalcaemic and hypocalcaemic disorders such as familial hypocalciuric hypercalcaemia (FHH) and autosomal dominant hypocalcaemia (ADH), respectively 4 . Furthermore, the CaSR, which is present as a dimer of ~240-310 kDa (reF. 5 ), represents a therapeutic target for such calcitropic disorders. In addition, cinacalcet, a CaSR positive allosteric modulator, is used in clinical practice to treat hyperparathyroid disorders, and calcilytic drugs that are CaSR negative allosteric modulators are being investigated as targeted therapies for symptomatic forms of ADH 6 . The CaSR is also expressed in other tissues, such as the intestines, pancreatic islets, lungs, brain, skin and vasculature, where it is involved in noncalcitropic actions that include regulation of molecular and cellular processes such as gene expression, proliferation, differentiation and apoptosis, as well as in influencing the physiological regulation of enteroendocrine hormone secretion, cardiac function, vascular tone and lung and neuronal development [7] [8] [9] [10] [11] [12] [13] [14] (Tables 1,2) . Furthermore, abnormal expression or function of the CaSR in these noncalcitropic tissues has been reported to contribute to the pathogenesis of cardiovascular diseases, asthma, Alzheimer disease, breast cancer and colon cancer 9, [14] [15] [16] . This Review focuses on the evolutionary origins, structure and signalling pathways of the CaSR, together with the roles of the CaSR in calcitropic and noncalcitropic diseases.
Structure of the CaSR
The CaSR belongs to the family C GPCRs, which have pivotal roles in neurotransmission, nutrient sensing and Ca 2+ homeostasis 17 . These receptors are functionally active as homodimers or heterodimers [18] [19] [20] and are
The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases -sensing receptor (CaSR) is a dimeric family C G protein-coupled receptor that is expressed in calcitropic tissues such as the parathyroid glands and the kidneys and signals via G proteins and β-arrestin. The CaSR has a pivotal role in bone and mineral metabolism, as it regulates parathyroid hormone secretion, urinary Ca 2+ excretion, skeletal development and lactation. The importance of the CaSR for these calcitropic processes is highlighted by loss-of-function and gain-of-function CaSR mutations that cause familial hypocalciuric hypercalcaemia and autosomal dominant hypocalcaemia, respectively , and also by the fact that alterations in parathyroid CaSR expression contribute to the pathogenesis of primary and secondary hyperparathyroidism. Moreover, the CaSR is an established therapeutic target for hyperparathyroid disorders. The CaSR is also expressed in organs not involved in Ca 2+ homeostasis: it has noncalcitropic roles in lung and neuronal development, vascular tone, gastrointestinal nutrient sensing, wound healing and secretion of insulin and enteroendocrine hormones. Furthermore, the abnormal expression or function of the CaSR is implicated in cardiovascular and neurological diseases, as well as in asthma, and the CaSR is reported to protect against colorectal cancer and neuroblastoma but increase the malignant potential of prostate and breast cancers.
characterized by the presence of a large extracellular domain (ECD), which contains a bilobed venus flytrap (VFT) module (Fig. 2) that binds ligands and is structurally similar to nutrient-scavenging bacterial periplasmic proteins 21 . The CaSR is considered to have arisen during vertebrate evolution 22 and is functionally active in vertebrates ranging from cartilaginous fishes to terrestrial mammals 22 . X-ray crystallography studies have demonstrated that the human CaSR has a glycosylated ECD, which binds extracellular Ca 2+ (Ca 2+ e ) at three distinct sites within the VFT module, and also at a site located between the VFT module and the cysteine-rich domain (CRD) 23 ( Fig. 2) . The CaSR also binds amino acids within the cleft of the VFT module 23, 24 ( Fig. 2) , and the binding of both Ca 2+ and amino acids might be required to fully activate the CaSR 23 . The CaSR VFT module is predicted to contain additional binding sites for anions such as phosphate and sulfate, and these anions probably stabilize the CaSR in an inactive conformation 23 . The CaSR is maintained as a dimer (Fig. 2 ) by covalent and noncovalent interactions that involve the amino-terminal VFT lobe of each monomer, and ligand binding induces closure of the VFT module, as well as extending the dimer interface to include the carboxy-terminal VFT lobe and the CRD 23 . These agonist-induced conformational changes of the CaSR ECD might lead to rearrangements of the helices within the transmembrane domain (TMD) that facilitate G protein binding and intracellular signal transduction 3 . The CaSR TMD consists of seven hydrophobic helical domains connected by three extracellular loops and three intracellular loops (Fig. 2) . The TMD anchors the CaSR in the plasma membrane and also has a critical role in signal transduction. Indeed, mutational analysis has identified residues within intracellular loops 2 and 3 that are essential for the activation of downstream effector proteins 25 . The CaSR TMD has not yet been crystallized; however, homology modelling studies using the related metabotropic glutamate receptor crystal structure indicate the presence of a cavity located between the midportion and the extracellular aspect of the CaSR TMD, which is the site of binding of positive allosteric modulators such as the phenylalkylamine calcimimetic drugs and negative allosteric modulators such as the amino alcohol calcilytic drugs 26 (Fig. 2) . The intracellular domain (ICD) of the CaSR regulates downstream signalling events 27 and also undergoes phosphorylation and ubiquitylation, which facilitates desensitization and degradation or recycling of the CaSR 28, 29 . Moreover, the ICD is considered to be the site of binding for the intracellular adaptor-related protein complex 2 (AP2) (Fig. 2) , which facilitates clathrin-mediated endocytosis of GPCRs such as the CaSR 30 .
CaSR signalling
The CaSR activates downstream signalling cascades by coupling to heterotrimeric guanine nucleotide binding proteins (G proteins) such as the G q/11 , G i/o and G 12/13 families of proteins 31, 32 . The G q/11 proteins are critical for CaSR signal transduction 33 , and germline mutations of G protein subunit α 11 (Gα 11 ) have been shown to cause hypercalcaemic and hypocalcaemic disorders 34 (Table 3) .
Through G q/11 family proteins, the CaSR activates phospholipase C to convert phosphatidylinositol 4,5-bisphosphate into diacylglycerol and inositol 1,4,5-trisphosphate, which in turn releases Ca 2+ from intracellular stores by binding to inositol 1,4,5-trisphosphate receptors on the endoplasmic reticulum and activates Ca 2+ influx via store-operated channels located in the plasma membrane 31 ( Fig. 2) . The lipid-derived second messenger, diacylglycerol, activates protein kinase C, which regulates protein phosphorylation cascades involved in cell survival, differentiation and proliferation such as those involving the mitogen-activated protein kinases (MAPKs) 31, 35 (Fig. 2 ). Key components of the MAPK cascade activated by the CaSR include extracellular-signal regulated kinase 1 (ERK1) and ERK2, p38 kinase and JUN N-terminal kinase 36, 37 . By coupling to the pertussis toxin-sensitive G i/o proteins, the CaSR suppresses adenylyl cyclase activation and cAMP production (Fig. 2) and also stimulates the activity of MAPKs such as ERK1 and/or ERK2 (reFs 31, 35, 36 ). The CaSR can also stimulate the ERK1 and/or ERK2 arm of the MAPK pathway via a G protein-independent mechanism involving the β-arrestin proteins 38, 39 . The CaSR has also been reported to couple to the G 12/13 proteins to activate RHOA, a small GTPase protein that has a role in serum response element-mediated gene expression by the CaSR 40 . CaSR signal transduction also determines the level of cell surface expression of this GPCR via a process known as agonist-driven insertional signalling, which increases anterograde trafficking of newly synthesized CaSRs to the plasma membrane (Fig. 2) and probably prevents the CaSR from undergoing functional desensitization in response to continual exposure to Ca 2+ e (reFs 41, 42 ). CaSR signalling and trafficking are also mediated by the σ-subunit of heterotetrameric AP2, and germline hypercalcaemia-causing loss-of-function AP2σ mutations impair CaSR endocytosis and reduce intracellular Ca 2+ and ERK1 and/or ERK2 signalling responses in CaSR-expressing cells 30, [43] [44] [45] (Table 3) . These CaSR-mediated signalling cascades modulate diverse physiological functions in calcitropic and noncalcitropic tissues, including hormone secretion, growth, survival, migration, adhesion and differentiation, as is discussed in subsequent sections. In calcitropic tissues, loss and
Key points
• The Ca 2+ -sensing receptor (CaSr) is a family C G protein-coupled receptor that is expressed on the cell surface as a dimer and signals via G proteins and β-arrestin.
• The CaSr regulates bone and mineral metabolism by influencing parathyroid hormone secretion, urinary Ca 2+ excretion, skeletal development and lactation.
• Germline CASR, GNA11 and AP2S1 mutations cause calcitropic disorders such as familial hypocalciuric hypercalcaemia and/or autosomal dominant hypocalcaemia.
• In noncalcitropic tissues, the CaSr influences biological processes including gastrointestinal nutrient sensing, secretion of insulin and enteroendocrine hormones, vascular tone and wound healing.
• abnormal expression or function of the CaSr is associated with primary and secondary hyperparathyroidism, ischaemic brain injury, cardiovascular disease, asthma and cancers of the breast, prostate and colon.
• CaSr-targeted calcimimetic and calcilytic drugs have therapeutic potential for calcitropic and noncalcitropic diseases.
www.nature.com/nrendo gain of CaSR expression and/or signalling lead to hypercalcaemic and hypocalcaemic disorders, respectively. However, in noncalcitropic tissues, reduced CaSR activity and/or signalling has been associated with disorders ranging from impaired wound healing to vascular calcification and colorectal carcinoma 11, 16, 46 , and upregulation of CaSR expression in cells and tissues with a low basal level of CaSR expression and activity, such as neurons and airway smooth muscle cells, has been reported to occur in brain injury and asthma 14, 47 , with the resulting increase in CaSR activity and signalling further contributing to disease progression. 64, 65 . Increases in Ca 2+ e and 1,25(OH) 2 D concentrations lead to negative feedback on the parathyroid glands, thereby inhibiting further PTH release. b | The CaSR is expressed in the following portions of the nephron: apical membrane of the proximal tubule, where it regulates 1,25(OH) 2 D synthesis and inorganic phosphate (P i ) excretion; basolateral membrane of the cortical thick ascending limb of the loop of Henle and the apical membrane of the distal convoluted tubule, where it regulates Ca 2+ reabsorption; the apical and the basolateral membranes of the collecting duct, where it regulates H + and water excretion; and the juxtaglomerular apparatus, where it regulates renin secretion 62, 69, 72 . c | During lactation, the CaSR in the mammary gland detects reductions in Ca 2+ e , which lead to increased PTH-related peptide (PTHrP) secretion from mammary epithelial cells into the circulation 9 . PTHrP acts on the PTH1R to increase bone resorption, which in turn releases Ca 2+ for milk production 9 . Stimulatory and inhibitory actions are indicated by solid lines with arrow heads and solid lines bar heads, respectively. naTure revIewS | EnDOCRInOLOGy 223, 224 Proliferation and lung branching morphogenesis (-) 224 Gastrointestinal system Gastric parietal cells H + excretion ( + ) 231, 232 Gastric mucosal cells Ghrelin secretion (-) 171, 228 Gastric G cells Gastrin secretion ( + ) 172 Duodenal I cells Cholecystokinin secretion ( + ) 234 Intestinal L cells GLP1 production ( + ) 171 PYY production ( + ) 171, 235 Colon cells Enhance barrier function ( + ) 243 Enteric nervous system modulation (-) 238 Fluid secretion (-) 237, 238 Proliferation (-) 10 Pancreatic islets α-Cells Glucagon secretion ( + ) . Crystal structures indicate that the CaSR might also bind anions such as phosphate (PO 4 3-) and sulfate (SO 4 2-) 23 . Low-molecular-mass molecules that allosterically increase or suppress CaSR activity and are referred to as calcimimetic or calcilytic compounds, respectively, have also been identified 6, 52 . Such calcimimetic and calcilytic compounds are either in clinical use or under investigation for the management of calcitropic and noncalcitropic disorders, which are associated with aberrant expression of the CaSR, or activating or inactivating mutations of the CaSR or its downstream signalling molecules 3, 14, 44, [53] [54] [55] . Several CaSR ligands, including l-amino acids and polyamines, induce biased signalling (also referred to as functional selectivity), thereby leading to the preferential activation of distinct intracellular signalling responses 31, 39 . Phenylalkylamine calcimimetics (cinacalcet and NPS-R568) and the amino alcohol NPS-2143 calcilytic compound have also been shown to cause biased signalling by preferentially modulating intracellular Ca 2+ signalling relative to phosphorylated ERK1 (pERK1) and/or pERK2 signalling 56 . CaSR-mediated biased signalling might explain the fact that the CaSR can have different levels of responsiveness to extracellular Ca 2+ and mediate diverse physiological functions in different cell systems in response to locally available ligands and allosteric factors. The mechanisms underlying CaSR-mediated biased signalling remain to be elucidated, and the characterization of a novel ADH-causing mutation, Arg680Gly, has led to the identification of a transmembrane salt bridge (Arg680-Glu767) (Fig. 3) , which is located at the entrance to the TMD allosteric modulator binding pocket and regulates signalling via a G protein-independent mechanism 38 . Indeed, mutations that disrupt this salt bridge were shown to upregulate β-arrestin-mediated signalling without altering G protein-dependent signalling 38 ( Fig. 3) . The Arg680Gly CaSR mutation also abrogated the effect of the NPS-2143 calcilytic 38 ( Fig. 3) , probably by disrupting a hydrogen bond interaction between the wild-type Arg680 residue and NPS-2143 (reF.
26
). These findings indicate that a structurally distinct class of CaSR negative allosteric modulators, such as the quinazolinone calcilytic compounds 52 , might be required to treat patients with symptomatic hypocalcaemia caused by the gain-of-function Arg680Gly CaSR mutation 38 .
Role of the CaSR in Ca
2+ homeostasis Ca 2+ e is critical for a diverse range of biological functions that include mineralization of bone matrix, neuronal and neuromuscular function, blood coagulation and provision of a constant supply of Ca 2+ for intracellular processes, including signal transduction and the synthesis and secretion of hormones 57 . The concentration of Ca 2+ e is tightly regulated by a homeostatic system consisting of the following four components: the parathyroid glands, which sense Ca 2+ e and secrete PTH; the kidneys and small intestine, which shift Ca 2+ between the extracellular fluid and the external environment; the skeleton, which is the main Ca 2+ reservoir and buffers acute changes in Ca 2+ e concentrations; and calcitropic hormones such as PTH and 1,25-dihydroxyvitamin D (1,25(OH) 2 D), which mediate interactions between the parathyroid glands and target calcitropic organs such as the bone, kidney and intestines 3 ( Fig. 1) . Moreover, during lactation, the mammary glands act as a calcitropic organ, which secretes PTH-related peptide (PTHrP) to mobilize Ca 2+ from bone 9 . The CaSR is expressed in the parathyroid glands, kidneys, bone and breast, and its calcitropic actions in these tissues are outlined in the following sections.
Parathyroid gland
The CaSR is most highly expressed in the parathyroid glands 2 , where it regulates PTH synthesis and secretion in an inverse manner 58 . Thus, increases in Ca 2+ e lead to CaSR-mediated suppression of PTH release, whereas a decrease in Ca 2+ e releases this suppression to promote tonic PTH release 58 . In keeping with these effects of the CaSR on PTH suppression, mice with a parathyroid-specific CaSR ablation develop severe hyperparathyroidism and hypercalcaemia 59 . In the parathyroid glands, the CaSR interacts with Klotho, a (Fig. 1a) .
Kidney
The CaSR is highly expressed in the basolateral membrane of the renal thick ascending limb (Fig. 1) , where it regulates Ca 2+ reabsorption independently of the actions of PTH 64, 65 . CaSR in the renal thick ascending limb is considered to have a key role in systemic Ca 2+ homeostasis by sensing increases in Ca 2+ e and promoting renal Ca 2+ excretion to defend against hypercalcaemia 66 . The effect of the CaSR in the thick ascending limb on renal Ca 2+ excretion is probably mediated by the claudin 14 tight junction protein, which regulates the paracellular reabsorption of divalent cations 63, 67, 68 . The CaSR is also expressed at a lower level in the proximal renal tubule 69 , where it regulates expression of the 1-α-hydroxylase enzyme 67 , thereby influencing 1,25(OH) 2 D synthesis 67, 70 . The proximal renal tubular CaSR also inhibits PTH-mediated phosphate excretion 71 . The CaSR is also expressed in the apical membrane of the distal convoluted tubule 69 and detects increases in tubular fluid Ca . Furthermore, the CaSR is expressed in the renal collecting ducts 69 , where it prevents the development of hypercalciuria-mediated nephrocalcinosis by increasing urinary acidification and water excretion 73 . Finally, the CaSR has been reported to be expressed in the juxtaglomerular apparatus, where it inhibits renin secretion 74 ; however, the relevance of this finding to blood pressure regulation remains to be established.
Skeleton
The CaSR is expressed within bone and the growth plate, and its roles in these tissues have been characterized using mice with osteoblast-specific and chondrocyte-specific ablations of the CaSR 59, 75, 76 . These studies have demonstrated that the chondrocyte CaSR has a critical role in growth plate chondrogenesis, longitudinal bone growth and skeletal mineralization, probably by counteracting PTHrP-PTH1R signalling 77 . Indeed, mice with chondrocyte-specific ablation of the CaSR have shortened long bones and undermineralization of the ribs, long bones and calvariae 59 . Mice with osteoblast-specific CaSR ablation also showed -sensing receptor (CaSR) is functionally active as a constitutive homodimer and can sometimes also form heterodimers with other family C G protein-coupled receptors such as the metabotropic glutamate receptors and GABA type B receptors in growth plate chondrocytes and the central nervous system [18] [19] [20] . The CaSR extracellular domain binds Ca 2+ at multiple sites within the lobes of the venus flytrap (VFT) module and the cysteine-rich domain (CRD). The CaSR also binds amino acids within the VFT cleft. Synthetic phenylalkylamine positive allosteric modulators (PAMs) and amino alcohol negative allosteric modulators (NAMs) bind to the CaSR transmembrane domain (TMD). The binding of Ca 2+ leads to G q/11 -dependent activation of phospholipase C (PLC) and the production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ) from membrane-bound phosphatidylinositol 4,5-bisphosphate (PIP 2 ). The increase in intracellular IP 3 levels facilitates the release of Ca 2+ from intracellular stores such as the endoplasmic reticulum. DAG activates protein kinase C (PKC), which in turn activates the phosphorylated extracellular-signal-regulated kinases 1 (pERK1) and/or pERK2 arm of the mitogen-activated protein kinase (MAPK) pathway. The CaSR also activates the G i/o proteins, which leads to inhibition of adenylate cyclase (AC)-mediated production of cAMP. These signalling events cause a decrease in parathyroid hormone (PTH) secretion and increase in urinary Ca 2+ excretion. CaSR cell surface expression is regulated by agonist-driven insertional signalling, which mediates anterograde receptor trafficking 41 , and by an endocytic complex comprising clathrin, β-arrestin and the heterotetrameric adaptor-related protein complex 2 (AP2), which mediates retrograde receptor trafficking 45 . Loss-of-function and gain-of-function mutations of the CaSR lead to familial hypocalciuric hypercalcaemia type 1 (FHH1) and autosomal dominant hypocalcaemia type 1 (ADH1), respectively ; loss-of-function and gain-of function mutations of the Gα 11 subunit are associated with FHH2 and ADH2, respectively ; and loss-of-function mutations of the AP2σ subunit are associated with FHH3 (reF.
3 ).
www.nature.com/nrendo reductions in bone mineralization and long bone size, as well as developing spontaneous long bone fractures 59, 75 . These findings occurred in association with impaired osteoblast differentiation and increased osteoclast activation and highlight a role for the osteoblast CaSR in skeletal development, mineralization and remodelling 75 .
Breast
The CaSR is expressed in human and mouse mammary epithelial cells, and its expression is increased during lactation 78, 79 . The CaSR promotes lactation by increasing the activity of the plasma membrane Ca 2+ -ATPase 2 (PMCA2), which is expressed on the apical plasma membrane of mammary epithelial cells and transports Ca 2+ from the mammary cells into milk 80 . Studies in mice have shown that during lactation, the breast CaSR also influences Ca 2+ e homeostasis in order to regulate the mobilization of skeletal Ca 2+ for milk production 9, 79 . Thus, in low Ca 2+ e states, reduced activation of the CaSR in breast tissue leads to increased PTHrP production from breast epithelial cells, which in turn stimulates osteoclastic resorption of Ca 2+ from bone 9 ( Fig. 1c) .
These systemic effects of the breast CaSR ensure a steady supply of Ca 2+ for milk production and also protect against maternal hypocalcaemia during lactation 9 .
CaSR in inherited calcitropic diseases
Loss-of-function mutations of genes encoding the CaSR give rise to hypercalcaemic disorders such as FHH type 1 (FHH1) and neonatal severe hyperparathyroidism (NSHPT) and might occasionally cause primary hyperparathyroidism (PHPT). Loss-of-function mutations of genes encoding the downstream Gα 11 and AP2σ signalling proteins give rise to FHH2 and FHH3, respectively. By contrast, gain-of-function mutations of genes encoding the CaSR and Gα 11 cause ADH type 1 (ADH1) and ADH2, respectively (Table 3) .
Hypercalcaemic disorders
FHH comprises a genetically heterogeneous group of autosomal dominant disorders, which are designated as FHH1-FHH3 (reF.
3 ) ( Table 3) . FHH is considered to be a rare disorder; however, the prevalence remains to be defined. One study involving patients with a known clinical diagnosis of FHH in the west of Scotland reported a prevalence of 1 per 78,000 (1.3 per 100,000) 81 . However, 81 . Another study that analysed the occurrence of AP2σ mutations in the exome data sets obtained from a stable Pennsylvanian population comprising 51,289 individuals identified four individuals with a hypercalcaemia-causing AP2σ mutation, thereby giving a prevalence of 7.8 per 100,000 for FHH3 (reF.
82
). Thus, the overall prevalence of FHH is likely to be higher than previously reported from clinical studies. FHH is characterized by mild-to-moderate elevations of serum concentrations of Ca 2+ , mild hypermagnesaemia and normal or elevated circulating concentrations of PTH 4 . FHH has a similar serum biochemical phenotype to PHPT, and these conditions are distinguished in clinical practice by assessment of urinary calcium excretion, as ~80% of patients with FHH have hypocalciuria with a calcium-to-creatinine clearance ratio <0.01 (reFs 83, 84 ).
However, a low calcium-to-creatinine clearance ratio is also observed in ~10% of individuals with PHPT, and thus mutational analysis of the known FHH-causing genes is of benefit for differentiating FHH from PHPT 85 .
FHH1. FHH1 (Online Mendelian Inheritance in Man
(OMIM) #145980) is the most common form of FHH, accounting for ~65% of all FHH cases 4 . This condition is usually benign and nonprogressive; however, chondrocalcinosis has occasionally been reported in patients with FHH who are >60 years of age 86 , and some patients develop recurrent pancreatitis 87 . FHH1 is caused by germline heterozygous loss-of-function mutations of the CASR gene, which is located on chromosome 3q21.1 (reFs 88, 89 ) (Table 3) , and, to date, >150 different CASR mutations have been reported in patients with FHH 3 . The majority (>85%) of these mutations are missense substitutions, and the remaining (<15%) are nonsense, deletion, insertion and splice site mutations that result in truncated CaSR proteins 4, 88 . The offspring of parents with FHH1 can sometimes harbour homozygous or compound heterozygous CASR mutations that lead to NSHPT (OMIM #239200), which is a potentially life-threatening disorder characterized by severe hypercalcaemia (serum concentrations of calcium are typically 3.5-5.0 mmol/l (the normal range is 2.10-2.55 mmol/l)), bone demineralization (which leads to fractures) and respiratory distress 4 (Table 3 ). In some patients with NSHPT, hypercalcaemia responds to treatment with the calcimimetic cinacalcet, but parathyroidectomy is usually required in the long term 90 . Some patients with the clinical features of FHH, but without CASR mutations, have autoimmune hypocalciuric hypercalcaemia (AHH), which is associated with the presence of autoantibodies against the CaSR and lymphocytic infiltrates within the parathyroid gland 91, 92 . The hypercalcaemia caused by AHH is sometimes responsive to glucocorticoid therapy 91, 92 . Loss-of-function mutations affect all regions of the CaSR protein; however, mutations commonly occur within the first 350 amino acid residues of the ECD, which contains three of the four Ca 2+ binding sites and the VFT cleft amino acid binding site 23, 24 . Indeed, this region is a hot spot for recurrently occurring mutations that cause FHH1, and some amino acid residues are also affected by multiple different loss-of-function mutations 3, 88 . Approximately 50% of the mutations causing FHH1 are predicted to impair the biosynthesis and post-translational processing of CaSR proteins within the endoplasmic reticulum or Golgi apparatus, thus leading to increased proteasomal degradation of these nascent receptors, with reduced anterograde trafficking and cell surface expression 93, 94 . Some other mutations causing FHH1, which are located in the ECD and TMD, have instead been demonstrated to induce biased signalling responses by switching the wild-type CaSR from preferentially coupling with intracellular Ca 2+ (Ca 2+ i ) signalling to a mutant receptor that signals equally via the Ca 2+ i and the pERK1 and/or pERK2 arms of the MAPK pathway, or that acts mainly through pERK1 and/or pERK2 (reFs 95, 96 ). Biased signalling has also been observed with an AHH-causing autoantibody, which increased CaSR-mediated accumulation The salt bridge is formed by the Arg680 residue located in the proximal portion of transmembrane helix 3 (TM3) (dark green) and the Glu767 residue located in extracellular loop 2 (ECL2). The Arg680-Glu767 salt bridge is situated at the entrance of the allosteric modulator binding pocket, which is formed by residues from TM3 and TM5-TM7 (reF.
26
). The Arg680 residue mediates the binding of the NPS-2143 calcilytic compound 26 . The Arg680-Glu767 salt bridge is associated with G protein-mediated signalling, whereas disruption of the salt bridge by the autosomal dominant hypocalcaemia (ADH)-causing Ca 2+ -sensing receptor (CaSR) mutation Arg680Gly (indicated in bold) selectively increases β-arrestin-mediated signalling, as well as abrogating the inhibitory effect of the NPS-2143 compound 38 . TMD, transmembrane domain. (Table 3) . To date, FHH2-causing mutations have been reported in four probands, and these affected individuals exhibit mild hypercalcaemia (albumin-adjusted serum concentrations of calcium <2.80 mmol/l (the normal range is 2.10-2.55 mmol/l)), normal serum concentrations of PTH and normal or low urinary calcium excretion 34, 54, 98 . The GNA11 mutations identified in patients with FHH2 comprise three missense substitutions, Thr54Met, Leu135Gln and Phe220Ser, and an in-frame isoleucine deletion at residue 200 (Ile200del) 34, 54, 98 . All these mutations have been demonstrated to impair CaSR-mediated signalling responses and are predicted to affect key domains of the Gα 11 subunit 34, 54, 98 . Thus, the Ile200del and Phe220Ser mutations are located within the Gα 11 GTPase domain and are predicted to impair the coupling of Gα 11 with the upstream GPCR (that is, CaSR) or downstream effector protein (that is, phospholipase C), respectively 34, 54 . However, the Leu135Gln mutation is located within the portion of the Gα 11 helical domain that interacts with downstream effectors, and the Thr54Met mutation is situated at the interface between GTPase and helical domains and is predicted to impair guanine nucleotide binding at this interface 34, 98 . These studies of FHH2 mutations have highlighted residues critical for Gα 11 function.
FHH3. FHH3 (OMIM #600740
) is the most severe form of FHH and is characterized by significantly increased serum concentrations of calcium and magnesium and a significantly reduced fractional excretion of calcium (FECa) compared with FHH1 (reFs 43, 99 ). Moreover, symptomatic hypercalcaemia, recurrent pancreatitis and cognitive dysfunction have been reported in some patients with FHH3 (reFs 43, 100 ). Some patients with FHH3 also have reduced BMD, but this finding is not associated with alterations in serum concentrations of PTH 43 . This disorder is caused by germline heterozygous loss-of-function mutations of the AP2S1 gene on chromosome 19q13.3, which encodes the AP2σ protein 30 (Table 3) . AP2S1 mutations have been reported in >60 probands with FHH to date, and >98% of affected individuals have a mutation affecting the AP2σ Arg15 residue, which gives rise to an Arg15Cys, Arg15His or Arg15Leu missense substitution 30, 43, 44, 99, [101] [102] [103] . To date, only one patient with FHH has been reported with a mutation not involving the Arg15 residue: the mutation involved the Met117 residue 82 . Patients harbouring the Arg15Leu AP2σ mutation have been shown to be more hypercalcaemic, with an earlier age of presentation than probands with Arg15Cys or Arg15His AP2σ mutations 43, 103 . Crystal structure analyses have demonstrated that the AP2σ Arg15 residue binds to cell surface cargo proteins 104 , and these FHH3-causing Arg15 mutations are predicted to disrupt an interaction between AP2 and the CaSR ICD, thereby diminishing endocytosis of this GPCR 30 . Indeed, in vitro studies have shown FHH3-causing AP2σ mutations to alter CaSR cell surface expression and endocytosis 30, 45 and to impair signal transduction in a dominant negative manner 43 . Thus, these studies highlight a role for AP2 in Ca 2+ e homeostasis.
Hypocalcaemic disorders, including ADH
ADH is caused by increased sensitivity of the CaSR signalling pathway to Ca 2+ e concentrations 34, 105 and has the opposite biochemical phenotype of FHH. Thus, patients with ADH have low serum concentrations of calcium, mild hypomagnesaemia, normal or low PTH concentrations and an inappropriately normal or elevated urinary calcium excretion 3, 106 . Approximately 50% of patients with ADH have symptomatic hypocalcaemia, and >30% of patients have renal and/or intra cerebral calcifications 3 (Table 3 ). Some patients with ADH who have marked CaSR activation also have Bartter syndrome type V, which is characterized by hypokalaemic alkalosis, renal salt wasting and hyperreninaemic hyperaldosteronism 107, 108 (Table 3) .
Active vitamin D metabolites, combined with adequate dietary calcium intake and/or use of calcium supplements, are currently used to treat patients with symptomatic ADH, although their use can predispose patients to the development of marked hypercalciuria, nephrocalcinosis, nephrolithiasis and renal impairment 105, 106 . Thus, if active vitamin D metabolites are required to treat symptomatic hypocalcaemia in ADH, then serum concentrations of calcium should be maintained just below the lower limit of the normal range. ADH is a genetically heterogeneous disorder with two described types (ADH1; OMIM #601198 and ADH2; OMIM #615361) 3 . ADH1 and ADH2 are caused by germline heterozygous gain-of-function mutations in CASR and GNA11, respectively 34, 88, 105, [109] [110] [111] (Table 3 ).
To date, >70 different ADH1-causing CaSR mutations have been identified 3 : ~95% of these are missense substitutions, whereas ~5% are in-frame or frameshift insertion or deletion mutations 88 . Structure-function analyses have shown ADH1 mutations to cluster within the second peptide loop of the CaSR ECD (residues 116-136) 112 , which contributes to the CaSR dimer interface 23, 24, 113 , and within the distal portion of the TMD (residues 819-837) 114 , which contributes to the conformational changes required for G protein binding 115 . Moreover, the Leu173 and Pro221 ECD residues are the site of both ADH and FHH mutations 88, 116 , and structural analysis indicates that these residues are located at the CaSR dimer interface and might influence the receptor conformational changes that occur upon agonist binding 117 . Some patients with hypoparathyroidism, which can be isolated or caused by autoimmune polyglandular syndrome type 1, have activating autoantibodies to the CaSR [118] [119] [120] . These patients can have mild and asymptomatic hypocalcaemia or develop hypocalcaemic seizures that require treatment with calcium and vitamin D preparations 119 . Six different gain-of-function missense GNA11 mutations (Arg60Cys, Arg60Leu, Arg181Gln, Ser211Trp, naTure revIewS | EnDOCRInOLOGy Val340Met and Phe341Leu) have been reported to cause ADH2 (reFs 34, [109] [110] [111] ), and affected individuals have a similar phenotype to patients with ADH1. However, patients with ADH2 often have milder alterations in urinary calcium excretion than those who have ADH1 (reF.
109
), and short stature has also been reported in two ADH2 kindreds 109, 121 . Structural modelling studies have shown ADH2 mutations to cluster at the interface between the helical and the GTPase domains of the Gα 11 protein, which mediates GDP-GTP exchange, and to be located at the Gα 11 carboxyl terminus, which is involved in GPCR-G protein coupling 3, 34, 111 .
The CaSR in common calcitropic diseases Altered CaSR expression is implicated in the pathogenesis of common parathyroid disorders such as PHPT and secondary hyperparathyroidism (SHPT). Moreover, CASR single nucleotide polymorphisms (SNPs) have been reported to be associated with hypercalciuria and nephrolithiasis.
Primary hyperparathyroidism
PHPT is associated with an increased set point for Ca 2+ e -mediated PTH release 122 , which indicates that altered CaSR function has a role in the pathogenesis of this disorder. In support of this idea, germline heterozygous or homozygous loss-of-function CASR mutations have occasionally been reported in patients with adult-onset PHPT 123 . However, somatic CASR mutations have not been identified in parathyroid tumours from patients with sporadic PHPT [124] [125] [126] . Instead, the parathyroid set point abnormalities associated with PHPT might be partly attributable to alterations in CaSR expression, which is reduced in the majority of hyperplastic and adenomatous parathyroid tumours 127, 128 . In keeping with this hypothesis, ex vivo studies have shown the set point for Ca 2+ e -mediated PTH release to be inversely related to the amount of CaSR expression in parathyroid adenomas 129 . This decreased expression of CaSR in some parathyroid tumours is not reported to be caused by alterations in CASR gene promoter methylation 130 but might be associated with downregulation of filamin A 131 , a scaffolding protein that interacts with the CaSR in parathyroid cells 132 . However, the mechanisms causing this reduced CaSR expression in parathyroid tumours remain to be fully elucidated. Common CASR polymorphisms influence the clinical severity of PHPT. In particular, the Arg990Gly SNP, which is located in the CaSR cytoplasmic domain, has been reported to be associated with reduced serum concentrations of PTH and increased urinary calcium excretion, as well as increased occurrence of nephrocalcinosis in patients with PHPT 133, 134 .
CKD and secondary hyperparathyroidism
SHPT is a common complication of chronic kidney disease (CKD) and can arise early in the pathogenesis of this disorder 135 . Altered CaSR function is involved in the progression of SHPT in patients with CKD 135, 136 . Thus, hypocalcaemia, which occurs as a consequence of hyperphosphataemia and reduced 1,25(OH) 2 D synthesis in CKD, inactivates the CaSR in the parathyroid, thereby increasing PTH secretion 135, 136 . CaSR activation is also decreased by the pathophysiological reduction in extracellular pH that occurs in CKD, which might increase PTH secretion and exacerbate SHPT 137 . Increases in PTH secretion in CKD over long periods of time are associated with increased parathyroid cell proliferation and parathyroid gland hyperplasia, and studies in uraemic rats have shown these changes to be accompanied by reduced CaSR expression 138, 139 ; however, calcimimetic treatment can upregulate such decreased CaSR expression 139 . The reduction in CaSR expression is most marked in the nodular parathyroid gland hyperplasia caused by advanced SHPT 135, 140 . Furthermore, ex vivo studies involving freshly excised parathyroid glands from patients with SHPT on haemodialysis have shown that CaSR expression inversely correlates with parathyroid gland weight and the set point for Ca 2+ e -mediated PTH release 141 . Studies in rats have shown that renal CaSR expression is also reduced in CKD and might contribute to the hypocalciuria associated with this disorder 142 .
Hypercalciuria and nephrolithiasis
Idiopathic hypercalciuria is associated with nephrolithiasis and can sometimes be familial 143 ; however, germline CASR mutations have not been identified in families with autosomal dominant inheritance of idiopathic hypercalciuria 144 . Although, common SNPs located within the coding and regulatory regions of the CASR gene have been implicated in nephrolithiasis in patient-based studies. The common Arg990Gly CASR SNP has been reported to be associated with an increased risk of hypercalciuric nephrolithiasis 145 , and a common CASR promoter-region SNP (rs6776158 (A>G)), which impairs CASR transcriptional activity in vitro and decreases CaSR expression within the renal medulla, has been reported to be associated with an increased risk of Ca 2+ -containing renal calculi 146 . The mechanisms underlying the development of nephrolithiasis in patients with the rs6776158 CASR promoter-region SNP remain to be established, as no alterations in urinary concentrations of calcium or phosphate were found in the patients studied 146 .
Drugs for calcitropic diseases
CaSR allosteric modulators, which comprise calcimimetic and calcilytic compounds, are being used as targeted therapies for parathyroid disorders and also for treating symptomatic hypercalcaemia and hypocalcaemia caused by germline loss-of-function and gainof-function mutations of the CaSR signalling pathway, respectively 52, 147 . , and type II calcimimetics are positive allosteric modulators, some of which are naturally occurring (for example, l-amino acids), whilst others are synthetic compounds, and these positive allosteric modulators increase the sensitivity of the CaSR to Ca 2+ e (reFs 3, 148 ). Calcimimetic compounds, which decrease www.nature.com/nrendo PTH secretion and parathyroid gland proliferation, are used for the treatment of hyperparathyroid disorders 149, 150 . Cinacalcet, a phenylalkylamine compound that binds to the CaSR TMD, was the first calcimimetic to be approved as a therapy for hyperparathyroid conditions such as secondary hyperparathyroidism owing to end-stage renal disease, inoperable forms of primary hyperpara thyroidism and parathyroid carcinoma 6 . Etelcalcetide, an intravenously administered synthetic polycationic peptide that acts as a type II calcimimetic and agonist of the CaSR 151 , was approved in 2017 for the management of SHPT in adults on haemodialysis 152 . Etelcalcetide binds to the Cys482 residue within the CaSR VFT module 153 . Calcimimetics are also a targeted therapy for symptomatic forms of FHH 52 and have been shown to improve the signalling responses of cells expressing loss-of-function CaSR, Gα 11 or AP2σ mutant proteins in vitro 44, 53, 54, 96, 154 and to lower serum concentrations of calcium in patients with symptomatic hypercalcaemia caused by FHH1-FHH3 (reFs 44, 54, 155, 156 ). Cinacalcet has also been successfully used to manage life-threatening hypercalcaemia in patients with NSHPT who have a heterozygous CaSR mutation, Arg185Gln 157 , but might be less effective in those with NSHPT caused by biallelic deletional CaSR mutations 158 .
Calcimimetics

Calcilytics
Calcilytics are synthetic negative allosteric modulators that bind to the CaSR TMD 26 and comprise two main classes of compounds -the amino alcohols (for example, NPS-2143, ronacaleret, NPSP795 and JTT-305/MK-5442) and the quinazolinones (for example, ATF936 and AXT914) 6 . These compounds were developed for the treatment of osteoporosis, as they induced a transient rise in PTH secretion, which had the potential to induce anabolic effects on bone mass 159 . However, NPS-2143, which is the first calcilytic to be investigated as an osteoporosis treatment, did not alter BMD in rats 160 , and this absence of a bone anabolic effect is probably a consequence of NPS-2143 having a large volume of distribution, which caused longterm systemic exposure and sustained elevations of plasma concentrations of PTH 161 . Calcilytics have been developed with improved pharmacokinetic and pharmacodynamic profiles compared with those of NPS-2143 (reF.
161 ); however, clinical trials have shown that calcilytics such as ronacaleret and JTT-305/MK-5442 are not effective for treating postmenopausal osteoporosis 162, 163 , and these compounds have instead been investigated as potential targeted therapies for ADH 52 . In vitro studies have shown that the NPS-2143 calcilytic rectifies the increased signalling responses associated with gain-of-function CaSR and Gα 11 mutations, which cause ADH1 and ADH2, respectively 53, 96, 164, 165 . However, NPS-2143 has limited efficacy for severe gain-of-function mutations, which cause Bartter syndrome type V 165 , whereas the quinazolinone-derived calcilytic drugs have successfully rectified constitutive activation caused by Bartter syndrome-associated CaSR mutations 166 . Calcilytics have also been assessed in vivo, and single-dose studies have shown that NPS-2143 significantly increases plasma concentrations of calcium and PTH in mouse models of ADH1 and ADH2 (reFs 55, 164, 167 ). Moreover, longer-term studies involving ADH1 mouse models have shown that the JTT-305/MK-5442 calcilytic prevents the development of nephrocalcinosis, which was observed in mice treated with the drug vehicle or recombinant PTH 168 . In a phase IIa clinical trial, intravenous administration of the NPSP795 calcilytic compound increased plasma concentrations of PTH and reduced urinary calcium excretion in five patients with ADH1 (reF.
169
).
Noncalcitropic roles of the CaSR
The CaSR is widely expressed in tissues not involved in Ca 2+ e homeostasis, indicating that it probably has noncalcitropic roles. In some noncalcitropic tissues, CaSR activation is mediated by local fluctuations in Ca 2+ e (for example, the release of Ca 2+ e within pancreatic islets during insulin granule exocytosis 170 ), whereas in other noncalcitropic tissues, the Ca 2+ e concentration might be stable, and instead the CaSR is activated by endogenous ligands and modulators other than Ca 2+ e (Table 2) . Thus, the gastrointestinal-expressed CaSR is activated by dietary amino acids and peptides, which in turn influence digestion, satiety and glucose metabolism [171] [172] [173] (Table 2) .
Moreover, polyamines such as spermine are present at high concentrations in the colon and brain and are considered to activate the CaSR in these tissues, thereby modulating physiological processes such as colonic fluid secretion and synaptic transmission 174, 175 (Table 2 ).
The noncalcitropic roles of the CaSR involve regulation of the following physiological and pathophysiological processes in a tissue-dependent manner: proliferation, differentiation and apoptosis; vascular tone; renal and intestinal water transport; inflammation; maintenance of the integrity of epithelial layers in the intestine and skin; neuronal development and function; and enteroendocrine hormone secretion [9] [10] [11] [12] [13] [14] 73, 171 (Table 1) . Furthermore, abnormal CaSR function or expression in noncalcitropic organs is associated with cancer, cardiovascular diseases, asthma, gastrointestinal disorders, Alzheimer disease, impaired glucose tolerance and poor wound healing 176, 177 ( Fig. 4) . Some of these physiological and pathophysiological noncalcitropic roles of the CaSR are reviewed briefly below.
Tumorigenesis
Expression of the CaSR, which regulates cell fate, is increased or decreased in different cancers, suggesting that the CaSR has roles as an oncogene or tumour suppressor in different organs. For example, CaSR expression is increased in metastatic breast and prostate cancers 16, 178, 179 , whereas CaSR expression is decreased in colorectal cancer and some neuroblastic tumours 16, 180 . Breast cancer. In breast cancer cells, the CaSR acts as an oncoprotein and increases proliferation and inhibits apoptosis 181 , probably by switching G protein coupling from G i α to G s α, leading to an upregulation of PTHrP expression 182 . This increase in PTHrP results in the inhibition of the apoptosis-inducing factor (AIF) and cell cycle inhibitor p27 Kip1 (also known as cyclin-dependent naTure revIewS | EnDOCRInOLOGy -sensing receptor (CaSR) has key physiological roles in calcitropic tissues (for example, parathyroid glands, kidneys, bone and breast) and in non calcitropic tissues (for example, brain, cardiovascular system, lungs, intestine, pancreas and skin). Altered CaSR activity in calcitropic tissues causes inherited diseases of Ca 2+ homeostasis 3 and contributes to the pathogenesis of both primary hyperparathyroidism (PHPT) and secondary hyperparathyroidism (SHPT). By contrast, alterations in CaSR function or expression in noncalcitropic tissues are associated with Alzheimer disease, cardiovascular disease, asthma and both positive and negative effects on various malignancies. ADH, autosomal dominant hypocalcaemia; FHH, familial hypocalciuric hypercalcaemia; PTH, parathyroid hormone.
www.nature.com/nrendo kinase inhibitor 1B), thereby reducing apoptosis and promoting cell proliferation, respectively 181 . Moreover, in vitro studies involving the stimulation of malignant breast carcinoma cells with Ca 2+ e or the R-568 calcimimetic have shown that the CaSR increases the migratory potential of these tumour cells and promotes the secretion of proangiogenic and chemotactic factors that are implicated in breast cancer metastases 183, 184 . Furthermore, metastatic breast cancer cells in bone that express the CaSR might exacerbate PTHrP-mediated osteolysis by sensing high concentrations of Ca 2+ released during bone remodelling 185 and thereby promoting further PTHrP secretion. Thus, the CaSR has been hypothesized to drive a vicious cycle of skeletal metastasis 186 . In support of this idea, PTHrP secretion from breast cancer cells is stimulated by high (7.5-10.0 mM) Ca 2+ e concentrations 186 , which are present in the bone microenvironment during remodelling 185 , and breast cancer cells overexpressing the CaSR have been shown to cause an increase in osteolytic lesions when injected intratibially into BALB/c nude mice 187 . These findings indicate that the CaSR is involved in the pathogenesis of breast cancer skeletal metastases.
Neural tumours. The CaSR is involved in the differentiation of neural progenitor cells and has a tumour suppressor role in malignancies affecting the developing nervous system. The CaSR is expressed in neuroblastic tumours, which comprise neuroblastomas, ganglioneuroblastomas and ganglioneuromas, and its expression in these tumours is associated with favourable prognostic outcomes such as low clinical stage and age at diagnosis of <1 year 188 . By contrast, in highly malignant and undifferentiated neuroblastomas, the CaSR has been shown to be epigenetically silenced, and overexpression of the CaSR or treatment with cinacalcet in neuroblastoma cell lines reduces tumorigenicity by decreasing proliferation and increasing apoptosis 180, 189 .
Prostate and colorectal cancers. The CaSR might also mediate the effects of dietary Ca 2+ on the development of prostate and colorectal cancer. Thus, a high dietary intake of Ca 2+ is reported to exacerbate prostate tumorigenesis by potentially acting on the CaSR and the TRPC6 channel, a Ca 2+ -permeable channel 190 . By contrast, dietary Ca 2+ is reported to be protective against colorectal cancer, an effect that is probably mediated by the CaSR, as it was observed only in patients with CaSR-expressing tumours 191 . In the colon, the CaSR has tumour suppressor roles and has the following effects: inhibits proliferation; induces apoptosis and differentiation; prevents epithelial-to-mesenchymal transition [192] [193] [194] [195] ; and suppresses canonical WNT signalling whilst activating the noncanonical WNT pathway 196 . Furthermore, CaSR expression has been demonstrated to be lost during colorectal tumorigenesis, mainly through epigenetic mechanisms [197] [198] [199] .
Nervous system
The CaSR is widely expressed in the central and peripheral nervous system, including nerve terminals and fibre tracts, myelin-producing oligodendrocytes, astrocytes and microglial cells 200, 201 . Moreover, the CaSR is considered to have a role in the development of the hippocampus, the granule cell layer of the cerebellum and the sympathetic nervous system, as well as in gonadotropin-releasing hormone neuronal migration [201] [202] [203] [204] . The CaSR modulates the growth of sympathetic axons and promotes dendritic growth within the hippocampus 204 . The CaSR might also regulate neuronal excitability within the hippocampus by regulating neuronal K + channels and Na + leak channel nonselective protein (NALCN) 12 . Furthermore, the CaSR might facilitate neuronal migration by sensing alterations in Ca 2+ e or polyamines such as spermine, which are present within the brain, and also by increasing the production of chemokines such as monocyte chemoattractant protein 1 (reFs 202, 203 ). The CaSR is also expressed in the subfornical organ, which is involved in Na + sensing and water intake 205 , and influences action potential firing in subfornical organ neurons 206 . CaSR activity is negatively modulated by increases in Na + concentration and ionic strength 207 , and the subfornical organ CaSR might sense alterations in the prevailing ionic composition of plasma, which in turn influences the central regulation of salt and water metabolism 12 .
Abnormal CaSR function has been implicated in disorders of the central nervous system such as Alzheimer disease, ischaemic brain injury and epilepsy. Indeed, a patient-based study showed the presence of a polymorphic dinucleotide repeat within intron 4 of CASR to be significantly associated with the occurrence of Alzheimer disease 208 . Moreover, in vitro studies have shown that the CaSR is activated by proteins such as the amyloid-β 1-42 peptide fragment (Aβ ) and apolipoprotein E, which are involved in the pathogenesis of Alzheimer disease 208, 209 , and, in turn, CaSR activation in astrocytes leads to increased production of Aβ and phosphorylated Tau protein, which are inhibited by treatment with the NPS-2143 calcilytic 210, 211 . The neuronal CaSR forms heteromeric complexes with the GABA B receptor 1 (GBR1) 18 , and mouse model studies have demonstrated in ischaemic brain injury that the stoichiometry of these complexes is altered with upregulation of CaSR expression and downregulation of GBR1, which potentiates ischaemic neuronal death 212 . These studies also revealed that calcilytic treatment was neuroprotective in mice with brain injury and that it improved learning and memory retention 47 . CaSR mutations have been reported in patients with epilepsy 213 , and in vitro studies of the CaSR-Arg898Gln mutation, which co-segregated with epilepsy in one family in which the proband was normocalcaemic 213 , revealed that the Arg898Gln mutation is a gain-of-function mutation that increases CaSR expression 214 .
Cardiovascular system
The CaSR is expressed in arterial vessels and influences cardiovascular function through direct effects within the vasculature. Thus, the CaSR is expressed in human vascular smooth muscle cells (VSMCs) and endothelial cells 215, 216 and has a role in VSMC proliferation 217 and probably also in the regulation of blood pressure and blood vessel tone 13 . Indeed, ablation of the VSMC CaSR in mice has been shown to cause endothelium-independent decreases in the contractility of the aorta and mesenteric arteries and to decrease diastolic and mean arterial blood naTure revIewS | EnDOCRInOLOGy pressures 13 . Furthermore, in rabbit mesenteric arteries, CaSR stimulation induced endothelium-dependent vasorelaxation through two different pathways -one involving the production of nitric oxide and the other involving activation of intermediate conductance Ca 2+ -activated K + (IKCa) channels 218 . The VSMC CaSR also protects against the development of vascular calcification, and histological studies of calcified atheromatous human lower-limb arteries have shown reduced expression of the CaSR 46 . These findings are supported by studies of primary VSMCs, in which loss of CaSR expression or overexpression of a loss-of-function mutant CaSR in these cells led to increased mineralization 46 . Furthermore, the CaSR represents a potential therapeutic target in patients with vascular calcification, and a randomized controlled trial involving patients with CKD on haemodialysis showed that cinacalcet treatment had beneficial effects on arterial calcification, particularly on calcification involving the cardiac valves 219 . The CaSR is also expressed in the heart and is functionally active in rodent ventricular cardiomyocytes, where it promotes apoptosis 220 and might have a beneficial role in protecting against myocardial ischaemic injury
221
. Moreover, patient-based studies have demonstrated that a common CaSR SNP, Ala986Ser, is associated with an increased risk of myocardial infarction 15, 222 , but it remains to be established whether this increased risk is a direct consequence of abnormal CaSR function within the heart or vasculature or is caused by an indirect effect of the polymorphic CaSR on Ca 2+ e homeostasis 15 .
Pulmonary development and function
The CaSR is expressed in human fetal lungs, where it promotes fluid secretion into the pulmonary lumen, which stimulates lung growth and development 223 ; studies in mice have also indicated a role for the CaSR in regulating lung branching morphogenesis 224 . The CaSR is also expressed in adult human and mouse airway smooth muscle and bronchial epithelium 14 , and CaSR expression is increased in the airways of people with asthma and in allergen-sensitized mice 14 . Overexpression of the CaSR is considered to be activated by polycations in the asthmatic airway mucosa, thereby leading to bronchoconstriction 14 . Calcilytic treatment diminished signalling responses that caused airway contractility, and nebulized calcilytic administration significantly suppressed airway hyperreactivity and inflammation in a mouse model of allergic asthma 14 . These observations highlight the potential of inhaled calcilytics as a treatment for asthma 14 . Pathological upregulation of CaSR expression has also been implicated in idiopathic pulmonary artery hypertension, and calcilytic treatment in rodents has been demonstrated to prevent the development of this disorder and ameliorate the secondary occurrence of right ventricular hypertrophy 225 .
Gastrointestinal tract
The CaSR, which is expressed in the gastrointestinal tract of amphibia, birds, fish and mammals 226 , has been reported to act as a nutrient sensor that promotes gastric acid secretion and activates or inhibits the release of key enteroendocrine hormones, as well as regulating intestinal fluid balance and intestinal barrier function and inflammation 10, 171, 226, 227 (Table 1) .
Nutrient sensing and enteroendocrine hormone secretion.
The CaSR senses nutrients such as Ca 2+ and aromatic amino acids within the lumen of the gastrointestinal tract and responds to alterations in the concentrations of these nutrients by regulating hormone secretion from enteroendocrine cells located throughout the gastrointestinal tract, such as gastrin-secreting G cells, ghrelin-secreting gastric cells, cholecystokinin-secreting I cells and glucagon-like peptide 1 (GLP1)-secreting and peptide YY (PYY)-secreting L cells [228] [229] [230] . The CaSR is expressed in gastrin-secreting G cells, and studies involving wild-type and CaSR-null mice have shown that activation of the CaSR by Ca 2+ and aromatic amino acids leads to gastrin secretion 172 . Gastrin promotes histamine release from gastric body enterochromaffin-like cells, which in turn increases acid secretion from gastric parietal cells 172 . The CaSR is also expressed in gastric parietal cells, and human studies have shown that this GPCR increases gastric acid secretion by influencing H + /K + -ATPase activity 231, 232 . Activation of the CaSR in the small intestine has also been shown to improve post-prandial glucose tolerance in wild-type rats 173 . This effect of the CaSR expressed in the gastrointestinal tract on glucose tolerance might be mediated by a reduction in gastric emptying rate 173 , as well as through effects on GLP1, which has a key role in increasing glucose-dependent insulin release 233 . Indeed, ex vivo studies involving mouse intestine have shown that the CaSR is expressed in GLP1-secreting L cells and also that oligopeptides increase GLP1 secretion by activation of the CaSR 233 . The CaSR expressed in the gastrointestinal tract also reduces food intake by modulating the secretion of enteroendocrine hormones 171 . Thus, the CaSR has been shown to inhibit the release of ghrelin and increase the secretion of PYY, which are neuroendocrine peptides involved in the hypothalamic regulation of appetite 171 . The CaSR might also exert these anorectic effects by increasing the secretion of GLP1 (reF.
171
), which in turn suppresses appetite following food ingestion, as well as by increasing cholecystokinin secretion from I cells 234 , which leads to a delay in gastric emptying. CaSR activation might also cause emesis, and studies involving mice have demonstrated that deoxynivalenol, which is an emesis-inducing toxin, acts by increasing CaSR-mediated secretion of cholecystokinin and PYY 235 . These findings potentially explain the gastrointestinal adverse effects such as nausea and vomiting experienced by >30% of patients on cinacalcet, which is used for pharmacological activation of the CaSR 152 . Moreover, cinacalcet has been shown to impair gastric emptying in rats 236 , whereas evocalcet, a newer orally active pyrrolidine-derived calcimimetic compound, did not alter gastric emptying in rats and was associated with reduced emesis compared with cinacalcet in marmosets 236 .
Intestinal fluid secretion. Activation of the CaSR within colon epithelial cells has been shown in rodent studies to inhibit fluid secretion induced by secretagogues such as cholera toxin 237 . Cholera toxin causes secretory diarrhoea by increasing cyclic nucleotide generation within www.nature.com/nrendo the colonic epithelium and also by stimulating the enteric nervous system to release secretagogues such as vasoactive intestinal peptide 238 . The CaSR in the colon counteracts these effects by activating phosphodiesterases via a phospholipase C-dependent mechanism, which degrades the cyclic nucleotides generated by cholera toxin, and by inhibiting the enteric nervous system 237, 238 . These findings reveal that the CaSR is a potential therapeutic target for secretory diarrhoea caused by bacterial toxins 237 .
Intestinal barrier function and inflammation. Alterations in intestinal epithelial barrier function are implicated in the pathogenesis of inflammatory bowel disorders such as Crohn's disease 239 . The CaSR is expressed in colonic epithelial cells as well as in colonic myofibroblasts, which are located at the basal surface of the epithelium and regulate epithelial barrier function 240, 241 . Cellular studies involving colonic myofibroblasts have shown that the CaSR increases secretion of bone morphogenetic protein 2 (BMP2), which promotes colonic epithelial barrier maturation 241 . The CaSR also inhibits tumour necrosis factor (TNF) secretion from colonic myofibroblasts 242 and, thus, this GPCR might protect against intestinal inflammation. The epithelial CaSR also has a key role in intestinal barrier function, and studies of intestinal epithelium-specific CaSR-null mice have shown reduced transepithelial resistance in association with reduced colonic expression of tight junction proteins such as claudin 2 (reF.
243
). This defect in epithelial barrier function was associated with an altered composition of the intestinal microbiome 243 that comprised a decrease in the amount of beneficial lactobacilli but an increase in Deferribacteraceae bacteria, which are linked to colitis 243 . This dysbiosis of the intestinal microbiota has been associated with pro-inflammatory responses in intestinal epithelium-specific CaSR-null mice 244 . Indeed, in response to chemically induced colitis, these mice had more severe colitis with delayed recovery compared with the CaSR-expressing littermate controls 243 .
Pancreatic islets and glucose homeostasis
The CaSR is highly expressed in pancreatic islet α-cells and β-cells 2, 245 , and studies of isolated human islets and insulin-secreting cell lines have shown that CaSR activation leads to the upregulation of phospholipase C and MAPK-mediated signalling responses in association with a transient rise in insulin and glucagon secretion [245] [246] [247] . Furthermore, studies involving an ADH1 mouse model known as nuclear flecks (Nuf) showed that CaSR activation in heterozygous (Casr +/Nuf ) and homozygous (Casr Nuf/Nuf ) mice was associated with impaired glucose tolerance compared with that seen in wild-type (Casr +/+ ) mice. This impaired glucose tolerance was ameliorated by calcilytic treatment 7 . Casr +/Nuf and Casr Nuf/Nuf mice also had hypoinsulinaemia and reduced pancreatic islet mass, which was associated with reduced β-cell proliferation 7 . In addition, Casr Nuf/Nuf mice showed a lack of glucose-mediated suppression of glucagon secretion, which was associated with altered α-cell membrane depolarization 7 . These in vivo and ex vivo studies have highlighted roles for the CaSR in both the regulation of pancreatic islet mass and α-cell and β-cell function.
Skin
Extracellular Ca
2+ is required for the maintenance of an intact epidermal barrier, and in vitro studies have shown that Ca 2+ e -mediated intracellular Ca 2+ mobilization has a key role in keratinocyte differentiation 248 . Furthermore, Ca 2+ e mediates wound healing and skin re-epithelialization following injury 249 . This effect is triggered by the epidermal CaSR, which upon activation promotes keratinocyte differentiation, survival and adhesion 250 . In keeping with these findings, the barrier function of the skin in epidermis-specific CaSR-null mice has been shown to be defective with impaired keratinocyte differentiation 251 . Moreover, mice with combined ablation of the CaSR and the vitamin D receptor in keratinocytes had delayed wound re-epithelialization as a consequence of impaired keratinocyte adhesion and migration 11 . These findings reveal the importance of Ca 2+ and vitamin D signalling for epidermal regeneration after injury 11 , which are analogous to the interactions between Ca 2+ and vitamin D that have been reported for intestine function and colorectal tumorigenesis 252 .
Conclusions
The CaSR is a dimeric family C GPCR that signals via G proteins and β-arrestin and has a pivotal role in bone and mineral metabolism by influencing PTH secretion, urinary Ca 2+ excretion, skeletal development, bone cell function and lactation. Germline loss-of-function and gain-of-function mutations of the CaSR or its intracellular partner proteins lead to inherited calcitropic disorders such as FHH1-FHH3, ADH1 and ADH2. Loss of CaSR expression in the parathyroids contributes to the development of PHPT and SHPT. The CaSR is also widely expressed in noncalcitropic tissues, where it influences physiological processes such as nutrient sensing and the secretion of insulin and enteroendocrine hormones, neuronal and pulmonary development, vascular tone and wound healing. Moreover, pathophysiological alterations in CaSR expression or function are associated with cancers of the breast, prostate and colon, as well as with ischaemic brain injury, cardiovascular disease and asthma. The CaSR is a pharmacological target for calcitropic disorders; calcimimetic drugs are an established medical therapy for hyperparathyroid disorders and are effective for symptomatic FHH and some forms of NSHPT. Calcilytic drugs might be a targeted therapy for ADH and could also have potential in other hypoparathyroid disorders. CaSR-targeted drugs are also being evaluated in noncalcitropic disorders, and novel strategies such as the use of inhaled calcilytics for asthma to minimize off-target effects are being evaluated in preclinical models. However, a key challenge for the pharmaceutical industry is to develop compounds that can selectively influence biased signalling responses by the CaSR, thereby providing an approach for modulating CaSR function in a tissue-specific and disease-specific manner. The emergence of such therapies will aid the clinical management of noncalcitropic disorders without leading to off-target effects in calcitropic tissues.
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